Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.00 | 0.00 | 260.50K | 123.44K | 3.10M | 698.47K | Gross Profit |
-19.70K | 0.00 | -13.36M | 116.72K | -8.26M | -195.33K | EBIT |
-20.06M | -28.59M | -20.09M | -18.13M | -14.77M | -2.82M | EBITDA |
-20.04M | -28.59M | -19.91M | -18.12M | -14.77M | -2.82M | Net Income Common Stockholders |
-19.57M | -27.52M | -19.03M | -17.91M | -14.81M | -2.88M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
9.75M | 97.54M | 13.25M | 23.05M | 40.75M | 13.95M | Total Assets |
11.07M | 98.60M | 14.51M | 24.94M | 42.47M | 14.78M | Total Debt |
209.49K | 110.52K | 622.00K | 351.29K | 248.91K | 319.00K | Net Debt |
-2.14M | -56.38M | -8.54M | -6.84M | -40.50M | -13.63M | Total Liabilities |
4.29M | 3.73M | 3.53M | 3.90M | 4.05M | 5.00M | Stockholders Equity |
6.78M | 94.87M | 10.98M | 21.04M | 38.42M | 9.78M |
Cash Flow | Free Cash Flow | ||||
-17.23M | -19.15M | -18.10M | -17.59M | -14.30M | -1.13M | Operating Cash Flow |
-17.24M | -19.15M | -18.09M | -17.35M | -14.30M | -1.13M | Investing Cash Flow |
-358.07K | -37.00M | 11.66M | -16.01M | 0.00 | 0.00 | Financing Cash Flow |
3.66M | 103.48M | 8.41M | -204.77K | 41.09M | 15.06M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
46 Neutral | $156.86M | ― | -52.00% | ― | -100.00% | 38.72% | |
46 Neutral | $239.72M | ― | -74.36% | ― | ― | -10.43% | |
45 Neutral | $164.25M | ― | -36.38% | ― | 88.63% | 18.78% | |
42 Neutral | $153.71M | ― | 2152.93% | ― | ― | 54.68% | |
38 Underperform | $157.84M | ― | -57.58% | ― | 15.18% | -9.47% | |
36 Underperform | $173.14M | ― | -53.27% | ― | ― | 2.53% |
Inhibikase Therapeutics has announced the resignation of Garth Lees-Rolfe as Chief Financial Officer, effective April 11, 2025. His departure was amicable, and he will continue to provide consulting services to the company until August 15, 2025. David McIntyre has been appointed as the new Chief Financial Officer effective April 14, 2025. McIntyre brings over two decades of experience in the life sciences sector, having held various executive roles in biotech and medical device companies. His appointment is expected to strengthen the company’s financial leadership and strategic direction.
Spark’s Take on IKT Stock
According to Spark, TipRanks’ AI Analyst, IKT is a Underperform.
Inhibikase Therapeutics is struggling financially, with consistent net losses and negative cash flow. The stock’s technical indicators are bearish, and the valuation is not compelling due to the negative P/E ratio. However, recent leadership changes provide a glimmer of hope for strategic improvement. The stock’s overall score reflects these concerns, with financial performance being the most significant drag on the score, mitigated slightly by positive corporate events.
To see Spark’s full report on IKT stock, click here.
On February 21, 2025, Inhibikase Therapeutics completed a merger with CorHepta Pharmaceuticals, making CorHepta a wholly-owned subsidiary. The transaction involved a $15 million payment in the form of company shares, with some shares contingent on future milestones. The company also announced leadership changes, appointing Chris Cabell as President and Head of Research and Development, and Vincent Aurentz to the Board of Directors, aiming to enhance its strategic positioning in the biopharmaceutical industry.
Inhibikase Therapeutics announced the resignation of Milton H. Werner as CEO and the appointment of Mark Iwicki, effective February 14, 2025. Werner’s departure was amicable, with a consulting agreement extending his service. Iwicki, a seasoned biopharmaceutical executive, brings extensive experience and is expected to advance the company’s lead product, IkT-001Pro, enhancing Inhibikase’s positioning in the cardiopulmonary therapeutic market. Additionally, Amit Munshi has been appointed as the new Chair of the Board, reflecting a strategic leadership shift aimed at driving growth and fulfilling unmet needs in PAH treatment.